Want to see BMRN full AI Analyst Report?
BioMarin Pharmaceutical (BMRN) Stock Price & Analysis
BMRN Stock Chart & Stats
- Day’s Range
- $57.86 - $59.37
- 52-Week Range
- $49.26 - $70.98
- Previous Close
- $57.49
- Volume
- N/A
- Average Volume (3M)
- 2.34M
- Market Cap
- $11.33B
- Enterprise Value
- $14.47B
- Total Cash (Recent Filing)
- $874.00M
- Total Debt (Recent Filing)
- $4.20B
- Price to Earnings (P/E)
- 154.0
- Beta
- 0.49
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Raised Guidance
Strong quarterly growth and raised full-year guidance indicate continued demand across BioMarin’s rare-disease portfolio. Broad-based commercial execution and expanding patient adoption can support durable revenue compounding beyond a single reporting period.
Strong Cash Generation
Robust operating and free cash flow gives BioMarin internal funding capacity for research, commercialization, acquisitions, and debt reduction. This supports strategic flexibility and reduces reliance on external capital while the company expands its product portfolio.
Durable Product Evidence
Long-term clinical benefits in a progressive rare disease strengthen confidence in treatment durability and ongoing patient value. Sustained outcomes may support physician adoption, treatment persistence, and the commercial potential of BioMarin’s newer products.
Bears Say
Profitability Compression
The sharp decline in operating and net profitability shows that recent revenue growth is not translating efficiently into earnings. If margins remain compressed, lower returns on equity could constrain shareholder value creation and reduce the durability of reported earnings.
Acquisition Financing Burden
Higher interest expense and near-term acquisition dilution weigh on earnings while BioMarin integrates Amicus and realizes planned synergies. The added financing burden can limit cash available for other investments until profitability and deleveraging improve.
Voxzogo Competitive Pressure
Patient switching creates a structural risk to Voxzogo’s retention, growth rate, and contribution to BioMarin’s portfolio. Continued competitive migration could reduce the product’s long-term expansion potential, particularly in the important U.S. market.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
What is BioMarin Pharmaceutical’s market cap?
When is BioMarin Pharmaceutical’s upcoming earnings report date?
How were BioMarin Pharmaceutical’s earnings last quarter?
Is BioMarin Pharmaceutical overvalued?
Does BioMarin Pharmaceutical pay dividends?
What is BioMarin Pharmaceutical’s EPS estimate?
How many shares outstanding does BioMarin Pharmaceutical have?
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
What is the TipRanks Smart Score and how is it calculated?
BioMarin Pharmaceutical Stock Smart Score
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander Hardy
- Employees
- 3,221
- Website
- www.biomarin.com
- Address
- 770 Lindaro Street, San Rafael, CA, 94901, US
BioMarin Pharmaceutical (BMRN) Earnings & Revenues
BMRN Company Deck
BMRN Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic, driven by 20% revenue growth, raised full-year guidance, strong Voxzogo retention and patient growth, rapid Amicus integration, substantial synergy expectations, and a broader commercial and clinical pipeline. Offsetting factors included year-over-year EPS pressure from acquisition financing and higher expenses, near-term Amicus dilution, Voxzogo competitive switching, order-timing variability, diagnostic challenges, and pending legal and clinical uncertainties. Highlights significantly outweighed the lowlights.
View all BMRN earnings summariesBMRN Net sales Breakdown
- 28.98% VIMIZIM
- 19.42% VOXZOGO
- 17.37% NAGLAZYME
- 12.56% PALYNZIQ
- 21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 4 | 8 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 8 | 0 | 4 |
